Claims for Patent: 10,231,965

Summary for Patent: 10,231,965

Title:	Molecules for administration to ROS1 mutant cancer cells
Abstract:	Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Inventor(s):	Lim; Jonathan (San Diego, CA), Ardini; Elena (Sesto San Giovanni, IT), Menichincheri; Maria (Milan, IT)
Assignee:	IGNYTA, INC. (San Diego, CA) NERVIANO MEDICAL SCIENCES S.R.L. (Nerviano, IT)
Application Number:	14/623,904
Patent Claims:	1. A method of treating cancer in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3, the method comprising administering to said patient a therapeutically effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-- (tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 2. A method according to claim 1, wherein said at least one target gene is ROS1. 3. A method according to claim 1, wherein said at least one target gene is selected from at least one of NTRK1, NTRK2, and NTRK3. 4. A method according to claim 1, wherein said cancer is selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer. 5. A method according to claim 4, wherein said cancer is selected from non-small cell lung cancer, neuroblastoma, and colorectal cancer. 6. A method of treating non-small cell lung cancer in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3, the method comprising administering to said patient a therapeutically effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-- (tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 7. A method according to claim 1, wherein said cancer is papillary thyroid cancer. 8. A method according to claim 1, wherein said cancer is pancreatic cancer. 9. A method according to claim 1, wherein said cancer is colorectal cancer. 10. A method according to claim 1, wherein said cancer is mammary analogue secretory carcinoma. 11. A method of treating a sarcoma in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3, the method comprising administering to said patient a therapeutically effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-- (tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 12. A method according to claim 6, wherein said at least one target gene is ROS1. 13. A method according to claim 6, wherein said at least one target gene is NTRK1. 14. A method according to claim 6, wherein said at least one target gene is NTRK2. 15. A method according to claim 6, wherein said at least one target gene is NTRK3. 16. A method according to claim 1, wherein said at least one target gene is NTRK1. 17. A method according to claim 1, wherein said at least one target gene is NTRK2. 18. A method according to claim 1, wherein said at least one target gene is NTRK3. 19. A method according to claim 11, wherein said at least one target gene is ROS1. 20. A method according to claim 11, wherein said at least one target gene is selected from at least one of NTRK1, NTRK2, and NTRK3.